In the latest Publication Perspective, published by the Video Journal of Biomedicine, lead study author of the recent Future Oncologyarticle, Susana Banerjee (Institute of Cancer Research, London, UK) discusses the real-world study and the conclusion that switching from olaparib capsules to tablets in women with ovarian cancer is manageable, in terms of toxicity.
Aim: Describe rates of prespecified adverse events in patients who switched from olaparib capsules to tablets. Patients & methods: Retrospective, observational cohort analysis using self-controlled, pre–post design. Data on patients with ovarian cancer who switched from olaparib capsules to tablets between January 2015 and February 2019 were obtained from a US claims database. Results: Among all patients (n = 48), proportion with any prespecified adverse event was 45.8% (95% confidence interval: 31.4–60.8) during initial 90 days’ capsule use and 35.4% (22.2–50.5) during initial 90 days’ tablets use; difference -10.4% (-28.8–9.0). Conclusion: Switching from olaparib capsules to tablets was manageable with no evidence of increased toxicity. This real-world study supports the manageable tolerability of olaparib in women with ovarian cancer.
About the Video Journal of Biomedicine:
The Video Journal of Biomedicine, published by Future Medicine, provides the missing link between high-quality research information and its intended audience, be that fellow experts, researchers in other fields, students and trainees, or the general public (including patients and caregivers). Through concise, high-quality videos, with the author on screen or via voice-over animation, researchers are able to personally explain their work, highlighting its importance, placing it in context, and discussing future implications.